Susquehanna International Group, LLP Otonomy, Inc. Call Options Transaction History

Susquehanna International Group, LLP

15 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	SELL	$0.25 - $2.24 $37,525 - $336,224	-150,100 Reduced 68.98%	67,500 $20,000
Q2 2022 Aug 15, 2022	BUY	$1.72 - $2.51 $22,188 - $32,378	12,900 Added 6.3%	217,600 $453,000
Q1 2022 May 16, 2022	BUY	$1.72 - $2.47 $37,324 - $53,599	21,700 Added 11.86%	204,700 $491,000
Q4 2021 Feb 14, 2022	SELL	$1.69 - $2.31 $10,140 - $13,860	-6,000 Reduced 3.17%	183,000 $381,000
Q3 2021 Nov 15, 2021	BUY	$1.22 - $2.2 $69,418 - $125,180	56,900 Added 43.07%	189,000 $363,000
Q2 2021 Aug 11, 2021	BUY	$2.06 - $2.67 $139,668 - $181,026	67,800 Added 105.44%	132,100 $295,000
Q1 2021 May 17, 2021	SELL	$2.49 - $6.23 $338,640 - $847,280	-136,000 Reduced 67.9%	64,300 $164,000
Q4 2020 Feb 16, 2021	BUY	$3.48 - $6.47 $357,048 - $663,822	102,600 Added 105.02%	200,300 $1.3 Million
Q3 2020 Nov 16, 2020	BUY	$3.16 - $4.36 $308,732 - $425,972	97,700 New	97,700 $396,000
Q4 2018 Feb 14, 2019	SELL	$1.51 - $2.93 $355,605 - $690,015	-235,500 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$2.6 - $3.95 $510,380 - $775,385	196,300 Added 500.77%	235,500 $648,000
Q2 2018 Aug 14, 2018	SELL	$3.7 - $4.75 $34,780 - $44,650	-9,400 Reduced 19.34%	39,200 $151,000
Q1 2018 May 15, 2018	SELL	$4.05 - $6.1 $1.46 Million - $2.21 Million	-361,700 Reduced 88.16%	48,600 $204,000
Q4 2017 Feb 14, 2018	BUY	$2.8 - $5.55 $909,440 - $1.8 Million	324,800 Added 379.88%	410,300 $2.28 Million
Q3 2017 Nov 14, 2017	BUY	$3.2 - $20.8 $273,600 - $1.78 Million	85,500	85,500 $278,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.